BridgeBio Pharma, Inc.

Healthcare · Biotechnology · United States

Last price 74.95 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.65B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective ...